Editas Medicine Inc

Latest Results (18.10.2025):

Editas Medicine Inc. reported its financial results for the third quarter of 2024, highlighting significant developments in its research and development activities alongside notable changes in its financial performance compared to the same period in the previous year.

Increase in Net Loss

For the three months ended September 30, 2024, Editas Medicine Inc. reported a net loss attributable to common stockholders of $62.1 million, or $0.75 per share, compared to a net loss of $45.0 million, or $0.55 per share, for the same period in 2023.

Decline in Research and Development Revenues

Collaboration and other research and development revenues decreased significantly to $0.1 million for the three months ended September 30, 2024, down from $5.3 million in the corresponding period of 2023. This decline is primarily due to the absence of the upfront payment received in 2023 from the non-exclusive license to Vor Bio.

Increase in Research and Development Expenses

Research and development expenses rose by $7.1 million to $47.6 million for the three months ended September 30, 2024, compared to $40.5 million for the same period in 2023. The increase is mainly attributed to higher clinical and manufacturing costs related to the accelerated progression of the reni-cel program and costs associated with in vivo research and discovery.

Growth in General and Administrative Expenses

General and administrative expenses increased by $3.1 million to $18.1 million for the three months ended September 30, 2024, from $15.0 million in the same period of 2023. The rise is primarily due to higher employee-related expenses resulting from increased headcount to support business operations and the advancement of the reni-cel program.

Strengthened Cash Position

Editas Medicine Inc. ended the third quarter of 2024 with approximately $265.1 million in cash, cash equivalents, and marketable securities. This figure is expected to increase to approximately $322.1 million following the receipt of an upfront cash payment of $57 million from DRI Healthcare Trust under the sale of certain future license fees and other payments.